Previous close | 2.8000 |
Open | 2.8300 |
Bid | 2.6900 x 1200 |
Ask | 2.7300 x 600 |
Day's range | 2.7000 - 2.9400 |
52-week range | 1.1400 - 3.3300 |
Volume | |
Avg. volume | 2,035,693 |
Market cap | 265.905M |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2000 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.00 |
Gritstone bio, Inc. ( NASDAQ:GRTS ) just released its latest yearly results and things are looking bullish. Overall...
Gritstone bio ( NASDAQ:GRTS ) Full Year 2023 Results Key Financial Results Revenue: US$16.3m (down 18% from FY 2022...
-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluating Gritstone's "off-the-shelf" cancer vaccine, SLATE, combined with neoantigen cell therapy expected to begin in the coming months -- -- Gritstone incorporating GMP-grade raw materials in the manufacture of its samRNA v